Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCUS 
Arcus Biosciences Inc (RCUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RCUS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.36
1 Year Target Price $28.36
| 8 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.72% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio - | 1Y Target Price 28.36 |
Price to earnings Ratio - | 1Y Target Price 28.36 | ||
Volume (30-day avg) 13 | Beta 0.89 | 52 Weeks Range 6.50 - 18.98 | Updated Date 08/29/2025 |
52 Weeks Range 6.50 - 18.98 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -1.12 | Actual - |
Profitability
Profit Margin -113.74% | Operating Margin (TTM) -5% |
Management Effectiveness
Return on Assets (TTM) -18.69% | Return on Equity (TTM) -50.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 327232655 | Price to Sales(TTM) 4.31 |
Enterprise Value 327232655 | Price to Sales(TTM) 4.31 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA 3.96 | Shares Outstanding 106431000 | Shares Floating 59888710 |
Shares Outstanding 106431000 | Shares Floating 59888710 | ||
Percent Insiders 34.76 | Percent Institutions 67.52 |
Upturn AI SWOT
Arcus Biosciences Inc
Company Overview
History and Background
Arcus Biosciences Inc. was founded in 2015. It's a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. It has collaborations with Gilead Sciences and other pharmaceutical companies.
Core Business Areas
- Immunotherapy Development: Arcus focuses on developing novel cancer immunotherapies targeting multiple mechanisms in the tumor microenvironment.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Collaborations: Arcus collaborates with pharmaceutical companies to advance its pipeline.
Leadership and Structure
Terry Rosen serves as CEO. The company has a board of directors overseeing strategic direction and a management team leading day-to-day operations.
Top Products and Market Share
Key Offerings
- Domvanalimab: An anti-TIGIT antibody being evaluated in various clinical trials for multiple cancers. Market share data is not publicly available as it is still in development. Competitors include Roche (TIGIT program).
- Etrumadenant: A dual adenosine A2a/A2b receptor antagonist being evaluated in clinical trials. Market share data is not yet available. Competitors include other adenosine antagonists in development.
- Quemliclustat: A small molecule CD73 inhibitor. Currently in trials. Competitors include other CD73 inhibitors in trials.
Market Dynamics
Industry Overview
The cancer immunotherapy market is rapidly growing, driven by the increasing prevalence of cancer and advancements in immunotherapy research.
Positioning
Arcus Biosciences Inc. is positioned as an innovative biopharmaceutical company developing novel cancer immunotherapies. Its competitive advantage lies in its differentiated approach to targeting the tumor microenvironment.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to be in the hundreds of billions of dollars. Arcus is positioned to capture a portion of this market through its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Innovative immunotherapy pipeline
- Strategic partnerships with Gilead and other pharmaceutical companies
- Experienced management team
- Strong financial position
Weaknesses
- Reliance on clinical trial success
- Limited revenue stream
- High R&D expenses
- Dependence on partnerships
Opportunities
- Successful clinical trial outcomes
- Expansion of pipeline through internal development and acquisitions
- Increased adoption of immunotherapy in cancer treatment
- Potential for regulatory approvals
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- GILD
Competitive Landscape
Arcus faces competition from large pharmaceutical companies with established immuno-oncology franchises, but has first or best in class potential in its novel TIGIT and A2a/A2b programs.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancements in its clinical pipeline and partnerships.
Future Projections: Future growth is dependent on the success of its clinical trials and regulatory approvals.
Recent Initiatives: Focus on advancing its clinical pipeline and strengthening partnerships.
Summary
Arcus Biosciences is a promising immunotherapy company with a novel pipeline and strong partnerships, particularly with Gilead. Its success hinges on the positive outcomes of ongoing clinical trials. Potential regulatory hurdles and competition from larger pharmaceutical companies pose significant risks. Positive data will drive future growth. The company needs to continue to execute on its partnerships to achieve positive returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are approximations and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcus Biosciences Inc
Exchange NYSE | Headquaters Hayward, CA, United States | ||
IPO Launch date 2018-03-15 | Co-Founder, Chairman & CEO Dr. Terry J. Rosen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 627 | Website https://www.arcusbio.com |
Full time employees 627 | Website https://www.arcusbio.com | ||
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.